Ammar Sabilarrohman
In a landmark development for neurotechnology, Science Corporation—the ambitious venture founded by former Neuralink president Max Hodak—has successfully implanted its vision-restoring "PRIMA" chip into a patient suffering from Stargardt disease. This milestone, announced by Hodak at the annual TechCrunch Disrupt conference, marks a significant departure from traditional brain-computer interface (BCI) approaches. By treating the retina as an extension of the central nervous system, Science Corporation is moving beyond simple peripheral devices to redefine how we interface with the human brain.
The PRIMA Breakthrough: Restoring Sight to the Blind
Stargardt disease, an inherited condition that causes the progressive death of light-sensing photoreceptors in the outer retina, has long been considered incurable. It leaves patients with a growing central blind spot that eventually renders daily tasks like reading, recognizing faces, or navigating familiar environments nearly impossible. Approximately 150,000 individuals worldwide suffer from this debilitating condition.
The PRIMA system offers a beacon of hope. Unlike gene therapies that aim to "fix" the underlying biology, PRIMA acts as a high-tech prosthesis. The procedure, which takes approximately one hour, involves placing a 2mm by 2mm chip directly beneath the degenerated photoreceptors in the back of the eye. Patients then wear specialized glasses equipped with cameras that capture the visual field, processing the light data and transmitting it wirelessly to the sub-retinal chip. The chip effectively mimics the function of the missing photoreceptors, converting light into electrical signals that the optic nerve can interpret.
The clinical results from the Sydney Eye Hospital trial in Australia have been encouraging. According to company reports, the first patient implanted in May demonstrated rapid progress during rehabilitation. By the first session, the patient was able to identify individual letters; by the second, they were successfully reading full words.
Chronology of Innovation: From Neuralink to Science Corp
To understand the significance of this achievement, one must look at the evolution of Max Hodak’s career. As a co-founder and former president of Neuralink, Hodak was instrumental in the early days of high-bandwidth neural interfaces. However, upon departing in 2021, he sought a different path—one that emphasized clinical viability and a more nuanced approach to brain-machine interaction.
- 2021: Max Hodak founds Science Corporation with the goal of developing advanced neural engineering that prioritizes long-term, sustainable medical outcomes.
- 2025: The company begins signaling a pivot toward broader neurological applications, emphasizing that their technology would sit on top of the brain rather than piercing deep into sensitive neural tissue.
- 2026 (April): Science Corporation publicly prepares for its first sensor placement in a human brain, signaling the maturation of its core platform.
- 2026 (July): The PRIMA chip receives official regulatory approval in Europe for patients suffering from geographic atrophy, an advanced form of macular degeneration.
- 2026 (May–October): The first Stargardt disease patient undergoes the successful PRIMA implantation in Australia, followed by the public reveal of the technology’s performance at TechCrunch Disrupt.
The Technical Philosophy: Vision as Electrical Potential
Hodak’s philosophy centers on a fundamental reclassification of what constitutes a "brain-computer interface." For years, the industry has focused on BCIs as tools for controlling computers—cursors, robotic limbs, or digital keyboards. Hodak argues that this definition is too narrow.
"The retina is part of the central nervous system," Hodak stated during his keynote. "We consider cochlear implants, retinal prostheses, and motor prostheses all to be different types of BCIs."
By treating vision as nothing more than "electrical potential" traveling down the optic nerve, Science Corporation has demystified the process of sight. If a device can deliver the correct signal to the brain, the brain can "see," regardless of whether the original biological camera (the eye) is functional.
However, current technology is not yet a replacement for natural sight. "It’s like looking through a straw," Hodak admitted, acknowledging the limitations of the current 2mm by 2mm implant. "It is not a big field of view with color vision. It’s a patch in the central vision where it’s black and white, but it is sharp." The company is already developing the next generation of the chip, aiming to tackle the complex engineering challenges of curvature in the eye and higher electrode density to reach near-native visual acuity within the next five years.
Beyond Sight: The Future of Neural Engineering
While vision restoration is the current "proof of concept" for Science Corporation’s business model, the company’s ambitions are vast. Their core BCI sensor is designed to be implanted beneath the skull, resting on the surface of the brain. This is a deliberate contrast to the "stabbing" method used by companies like Neuralink, which insert electrodes directly into brain tissue to record activity.
The Near-Term Roadmap
Hodak confirmed that the company is currently working on an undisclosed clinical indication involving a major neurodegenerative disease. Beyond that, the company is looking at stroke rehabilitation. In cases where brain tissue has died, the potential exists to bypass damaged areas or create new "cortical bridges" that connect deep brain structures to functional areas. "If you can get connections into the deep brain in two different areas," Hodak suggested, "you can imagine adding new cortical areas, just like adding new brain areas entirely."
The Long-Term Vision: Engineering the Mind
The ultimate mission of Science Corporation, as described by its founder, is to understand the mechanics of the human mind. Hodak is candid about his desire to move beyond fixing medical ailments to potentially enhancing human cognitive function.
He posits a future where BCIs are not just medical implants for the severely disabled, but common tools for aging populations. While he clarifies that the company is not designing products for "healthy 40-year-olds," he believes that as people reach 60 or 70, the integration of BCI technology will become a necessity for maintaining cognitive health. "We want to figure out how to extend not just lifespan but health span," he noted.
Implications for Society and Medicine
The rise of Science Corporation signals a maturation of the BCI market. By focusing on commercial availability in Europe and proven clinical applications like Stargardt disease, the company is avoiding the "vaporware" trap that has plagued many neurotech startups.
However, the transition from therapeutic restoration to human enhancement brings a host of ethical questions. If we can successfully "add new brain areas," we are effectively moving from medicine to augmentation. The ability to record and interpret neural signals—and eventually provide input to them—will necessitate a new framework for "neuro-rights," ensuring that as we learn to "build engineered brains," we maintain the sanctity of human identity.
For now, the focus remains on the patient in Sydney who, for the first time in years, is reading words thanks to a 2mm silicon patch. As Science Corporation continues to refine its technology, the line between the biological brain and the digital world will continue to blur, ushering in an era where sight, memory, and cognitive capacity may soon be as upgradeable as the software on a smartphone.
The path ahead is clear, according to Hodak. With a "next generation" device already in the pipeline for human testing within the next twelve months, the company is moving at a pace that suggests the future of neuro-augmentation is no longer a matter of "if," but "when."
Asro
Basiran
